18-MC

This article was originally published on Microdose and appears here with permission. MindMed ended its 2021 news cycle on a somewhat mehhh note. In late December we reported that the FDA has put a hold on MindMed’s submission for its Phase 2b trial of LSD for the treatment...

MindMed Posts 2020 Financials, New MDMA Dosing Study and 18-MC Patent Application MindMed (OTCQB:MMEDF) released its full-year 2020 financial results.  The company posted a net and comprehensive loss of $35.1 million for the year ended Dec. 31, 2020. Its total assets at the end of the...

Health Canada Considers MDMA And Psilocybin 'Special Access' Program This week, Health Canada opened a public consultation on its “proposal to restore potential access to restricted drugs through the Special Access Program (SAP).” The SAP allows healthcare professionals to...

District of Columbia To Include Psychedelics Decriminalization Measure on November Ballot The District of Columbia will likely become the nation’s second jurisdiction to include a psychedelics decriminalization measure in November. Oregon made a similar announcement last week, and will...

Earlier this year, Canopy Growth (NYSE: CGC) co-founder and former CEO Bruce Linton invested in a neuropharmaceutical company, Mind Medicine Inc. MindMed is a psychedelic research company that’s developing non-hallucinogenic medicine from psychedelic sources. The company has also...